Skip to content

Breast Cancer Health Center

Font Size

Lobular Carcinoma In Situ

    Introduction

    The term lobular carcinomain situ (LCIS) is misleading. This lesion is more appropriately termed lobular neoplasia. Strictly speaking, it is not known to be a premalignant lesion, but rather a marker that identifies women at an increased risk for subsequent development of invasive breast cancer. This risk remains elevated even beyond 2 decades, and most of the subsequent cancers are ductal rather than lobular. LCIS is usually multicentric and is frequently bilateral. In a large prospective series from the National Surgical Adjuvant Breast and Bowel Project with a 5-year follow-up of 182 women with LCIS managed with excisional biopsy alone, only eight women developed ipsilateral breast tumors (four of the tumors were invasive).[1] In addition, three women developed contralateral breast tumors (two of the tumors were invasive).

    Recommended Related to Breast Cancer

    About This PDQ Summary

    Purpose of This Summary This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of breast cancer and pregnancy. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. Reviewers and Updates This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment...

    Read the About This PDQ Summary article > >

    Treatment Option Overview

    Most women with LCIS have disease that can be managed without additional local therapy after biopsy. No evidence is available that re-excision to obtain clear margins is required. The use of tamoxifen has decreased the risk of developing breast cancer in women with LCIS and should be considered in the routine management of these women.[2] The NSABP-P-1 trial of 13,388 high-risk women comparing tamoxifen to placebo demonstrated an overall 49% decrease in invasive breast cancer, with a mean follow-up of 47.7 months.[2] Risk was reduced by 56% in the subset of 826 women with a history of LCIS, and the average annual hazard rate for invasive cancer fell from 12.99 per 1,000 women to 5.69 per 1,000 women. In women older than 50 years, this benefit was accompanied by an annual incidence of 1 to 2 per 1,000 women of endometrial cancer and thrombotic events. (Refer to the PDQ summary on Breast Cancer Prevention for more information.)

    Bilateral prophylactic mastectomy is sometimes considered an alternative approach for women at high risk for breast cancer. Many breast surgeons, however, now consider this to be an overly aggressive approach. Axillary lymph node dissection is not necessary in the management of LCIS.

      1|2

      Today on WebMD

      Breast Cancer Overview
      From self-exams and biopsies to reconstruction, we’ve got you covered.
      Dealing with breast cancer
      Get answers to your questions.
       
      woman having mammogram
      Experts don’t agree on all fronts, but you can be your own advocate.
      woman undergoing breast cancer test
      Many women worry. But the truth? Most abnormalities aren’t breast cancer.
       
      Breast Cancer Treatments Improving
      VIDEO
      Resolved To Quit Smoking
      SLIDESHOW
       
      Woman getting mammogram
      Article
      Screening Tests for Women
      SLIDESHOW
       
      ovarian cancer overview slideshow
      SLIDESHOW
      serious woman
      Article
       
      what is your cancer risk
      HEALTH CHECK
      10 Ways to Revitalize Slideshow
      SLIDESHOW
       

      WebMD Special Sections